The members of the TCL1 proto-oncogene family (TCL1, MTCP1, and TCL1b) bind to Akt1, increasing its phosphorylation status and kinase activity. This is thought to be secondary to the formation of TCL1-Akt oligomers within which Akt is preferentially phosphorylated. Here we show that, in contrast to Akt1 and Akt2, which bind to all members of the TCL1 family, Akt3 specifically interacts with TCL1 but not with MTCP1 or TCL1b. This association is functional, as the presence of TCL1 but not MTCP1 or TCL1b increased Akt3 kinase activity in in vitro kinase assays. Functional specificity is determined by the Akt pleckstrin homology domain as chimeric Akt1, where Akt1 PH domain was replaced by that of Akt3 was no longer able to interact with MTCP1 or TCL1b and its kinase activity was solely enhanced by TCL1. Moreover, we show that, in TCL1-overexpressing SUPT-11 T-cell leukemia and P3HR-1 Burkitt's lymphoma cell lines, TCL1 interacts with endogenous Akt1, Akt2, and Akt3. TCL1 enhanced hetero-oligomerization of Akt1 with Akt3 and as a consequence facilitated transphosphorylation of Akt molecules, which may contribute to Akt activation and TCL1-induced leukemogenesis in vivo.
The members of the TCL1 proto-oncogene family (TCL1, MTCP1, and TCL1b) bind to Akt1, increasing its phosphorylation status and kinase activity. This is thought to be secondary to the formation of TCL1-Akt oligomers within which Akt is preferentially phosphorylated. Here we show that, in contrast to Akt1 and Akt2, which bind to all members of the TCL1 family, Akt3 specifically interacts with TCL1 but not with MTCP1 or TCL1b. This association is functional, as the presence of TCL1 but not MTCP1 or TCL1b increased Akt3 kinase activity in in vitro kinase assays. Functional specificity is determined by the Akt pleckstrin homology domain as chimeric Akt1, where Akt1 PH domain was replaced by that of Akt3 was no longer able to interact with MTCP1 or TCL1b and its kinase activity was solely enhanced by TCL1. Moreover, we show that, in TCL1-overexpressing SUPT-11 T-cell leukemia and P3HR-1 Burkitt's lymphoma cell lines, TCL1 interacts with endogenous Akt1, Akt2, and Akt3. TCL1 enhanced hetero-oligomerization of Akt1 with Akt3 and as a consequence facilitated transphosphorylation of Akt molecules, which may contribute to Akt activation and TCL1-induced leukemogenesis in vivo.
Serine/threonine kinase Akt (protein kinase B (PKB) 1 ) has a central role in the regulation of several signaling pathways controlling cell survival and proliferation. Currently, three mammalian isoforms (Akt1/PKB␣ Akt2/PKB␤, and Akt3/ PKB␥) of the kinase have been identified (1) (2) (3) . The isoforms share a high degree of structural homology with human Akt1 having 81 and 83% amino acid identity with Akt2 and Akt3, respectively. Akt1 and Akt2 knockout mice suggested distinct roles for each of the Akt family kinases (4, 5) . The kinases have two distinct functional domains: an N-terminal pleckstrin homology (PH) domain mediating protein-protein and protein-lipid interactions, and a C-terminal catalytic domain (3, 6, 7) .
The basic activation process of the Akt isoforms seems to be uniform. After the binding of growth factors to their cell surface receptors, Akt is translocated to the plasma membrane secondary to binding of the PH domain with products of the phosphoinositide 3-kinase pathway: phosphatidylinositide 3,4-bisphosphate and phosphatidylinositide 3,4,5-triphosphate. The activation of Akt is then regulated by phosphorylation on two regulatory sites: threonine 308/309/305 and serine 473/474/472 (Akt1/2/3, respectively) with phosphorylation of both required for maximal kinase activity (2) . Phosphorylation of the threonine residue occurs through the activity of phosphoinositide-dependent kinase 1 (PDK1) (3, 6, 7) . However, the identity of the kinase(s), putatively named PDK2, responsible for phosphorylation of the serine residue remains unclear. Recently, Akt kinase activity was demonstrated to be required for serine phosphorylation to occur in vitro, suggesting that Akt autophosphorylation might play a role in the process (8) . After activation, Akt has been shown to phosphorylate and inactivate a number of pivotal pro-apoptotic molecules including BAD, Nur77, and forkhead transcription factor (9 -12) . Several binding molecules of Akt have been reported that modulate Akt kinase activity (13) (14) (15) (16) .
Despite a high degree of structural identity and a similar activation process, there appears to be variability in the physiological roles of the Akt isoforms. Akt1 and Akt2 seem to be ubiquitously expressed, whereas the expression of Akt3 is more restricted with predominance toward heart, kidney, brain, testes, lung, and skeletal muscle (2, 3) . There is also evidence of differential regulation of the isoforms after induction by a common Akt activator. In human esophageal cancer cell lines, epidermal growth factor stimulation led to the activation of all Akt isoforms in some cell lines, whereas, in others, only Akt1 and Akt2 or solely Akt1 were phosphorylated and activated (17) . The identity of factors possibly contributing to isoformspecific regulation of Akt remains currently unknown.
We have found previously in a yeast two-hybrid screening that the proto-oncogene TCL1, implicated in human T-cell prolymphocytic leukemia (18 -20) , binds to Akt. In functional assays we found that all three proteins of the TCL1 family (TCL1, MTCP1, and TCL1b) were able to interact with Akt1 in mammalian cells and enhance Akt kinase activity (15, 16, 21) . Further, TCL1 was able to promote the formation of oligomeric TCL1-Akt protein complexes in which the kinase was preferentially phosphorylated and activated (15) .
Because TCL1, MTCP1, and TCL1b only share 30 -50% amino acid homology with each other, we hypothesized that they may show specificity in binding with the three Akt isoforms and differentially function as Akt co-activators. We fur-* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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ther hypothesized that, as TCL1 facilitates the formation of Akt oligomers, interaction with more than one Akt isoform might result in Akt hetero-oligomerization.
In the present report, we show that, in contrast to Akt1 and Akt2, which can interact with TCL1, MTCP1, and TCL1b, Akt3 specifically binds to TCL1. Further, only TCL1 can enhance Akt3 phosphorylation and kinase activity in vitro with PH domain as the functional determinant. Finally, we show that TCL1 binds to each of the Akt kinases in TCL1-overexpressing leukemic cells, and that TCL1 facilitates heterodimerization of different Akt molecules, which may contribute to the development of human malignancies associated with TCL1 overexpression.
EXPERIMENTAL PROCEDURES
Expression Vectors-Mammalian expression constructs (pCMV6-HAAkt1, pCMV6-HA-Akt2, pCMV2-Flag-TCL1, pME-18S-HA-TCL1, pCMV2-Flag-MTCP1, pCAGGS-Flag-TCL1b) and prokaryotic expression vectors for generation of GST fusion proteins (pGEX4T2-TCL1, pGEX4T2-MTCP1, and pGEX4T2-TCL1b) have been described previously (15) . Expression vectors for HA-Akt3K177M and HA-Akt3T305A/ S472A mutants were generated by site-directed mutagenesis using the QuikChange kit (Stratagene) with wild-type pCMV-HA-Akt3 (generous gift from B. Hemmings) as template. GFP-tagged HA-Akt3 (GFP-HAAkt3) was generated by digesting pCMV-HA-Akt3 and ligating the insert with the pEGFP-C2 (CLONTECH) vector. Expression vectors for full-length flag-Akt3, flag-PHAkt3 (amino acids 1-119 of Akt3), and flag-cAkt3 (amino acids 120 -479) were generated by PCR (primer pairs 5Ј-ATCGAATTCATGAGCGATGTTACCATTGTGAAG and 5Ј-ATCAG-ATCTTTATTCTCGTCCACTTGCAG, 5Ј-ATCGAATTCATGAGCGATG-TTACCATTGTGAAG and 5Ј-ATCAGATCTTTAACAATTCATTCTCTC-CTCTTC, and 5Ј-ATCATCGAATTCAGTCCAACTTCACAAATTGAT and 5Ј-ATCAGATCTTTATTCTCGTCCACTTGCAG, respectively) with pCMV-HA-Akt3 as template and introducing a 5Ј EcoRI site and a 3ЈBglII site. PCR products were then subcloned to EcoRI/BamHI-digested pCMV2-Flag cassette (Sigma). The chimeric pME-18S-HA-Akt3/ Akt1 construct was generated by PCR amplifying the coding sequences of the first 119 amino acids of Akt3 (PH-Akt3) and that of amino acids 121-480 of Akt1 (C-terminal Akt1), and subcloning both inserts into the pME-18S-HA cassette (15) .
Cell Culture, Immunoprecipitation, and Western Blotting-293T cell line obtained from ATCC was maintained in Dulbecco's modified Eagle's medium (4.5 g/liter glucose) supplemented with 10% fetal calf serum and 1% penicillin/streptomycin. SUP-T1 (ATCC), SUPT-11 (20) (generous gift from M. H. Stern), and P3HR-1 (HTB-62) (ATCC) cell lines were maintained in RPMI 1640 supplemented with 10% fetal calf serum and 1% penicillin/streptomycin.
For co-immunoprecipitation experiments 293T cells were co-transfected with a total of 10 g (5 g of each plasmid) of indicated plasmids/ 10-cm diameter dish, except for the experiment demonstrating enhanced interaction of Akt1 with Akt3 in the presence of TCL1 in which 1 g of pCMV-HA-Akt1 and 1 g of pCMV2-Flag-Akt3 were transfected together with 8 g of pME18S-TCL1-myc or PCMV empty vector (sham). 48 -72 h after transfection, cells were washed once with ice-cold PBS and lysed with ice-cold Brij 97 lysis buffer (0.875% Brij 97 (Sigma), 0.125% Nonidet P-40, 150 mM NaCl, 10 mM Tris-HCl (pH7.5), and 2.5 mM EDTA with protease inhibitor mix (Complete, Roche Molecular Biochemicals) added. Lysates were precleaned for 1 h with 50/50% (v/v) protein A/protein G mix and immunoprecipitated for 4 h at 4°C with anti-HA (3F10, Roche), anti-Flag (M2, Sigma), or anti-mouse-IgG as control. The samples were washed five times with ice-cold lysis buffer, after which SDS sample buffer was added, the samples resolved on 4 -20% Tris-glycine gels (Invitrogen) and immunoblotted with monoclonal horseradish peroxidase-conjugated anti-HA antibody (3F10, Roche Molecular Biochemicals) or monoclonal anti-Flag antibody (M2, Sigma).
In experiments using Sup-T1, SupT-11, and P3HR-1 cell lines, precleaning was performed using protein G and immunoprecipitation was done overnight at 4°C using isoform-specific anti-Akt1, anti-Akt2, or anti-Akt3 antibodies (Upstate Biotechnologies, Inc.) with sheep normal serum as control. Western blotting for Akt was done using anti-pan-Akt antibody (New England Biolabs) or monoclonal anti-TCL1 antibody 27D6 (generous gift from R. Bichi).
GST Pull-down Assay-In vitro translation reactions were performed using the TNT coupled reticulocyte lysate system (Promega), using [ 35 S]methionine (Amersham Biosciences, Inc.), T7 polymerase, and human full-length Akt3 in pBluescript SK II (Stratagene). 10 l of in vitro translated Akt3 protein product was mixed with 6 g of each GST fusion protein and 20 l of glutathione-Sepharose 4B beads (Amersham Biosciences, Inc.) (control, TCL1, MTCP1, or TCL1b) in 400 l of NETN buffer (20 mM Tris (pH 8.0), 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40), incubated for 3 h at 4°C, and washed three times with NETN buffer. After the final wash 20 l of 2ϫ SDS sample buffer was added to each reaction, and the samples were resolved on 4 -20% Tris-glycine gels (Invitrogen) and autoradiographed.
In Vitro Akt Kinase Assay-The assays were performed using the Akt kinase assay kit (Cell Signaling Technologies) with the modifications described previously (15) . For the preparation of HA-Akt1, HA-Akt2, HA-Akt3 HA-Akt3/Akt1, and GFP-HA-Akt3 (wild-type and K177M). 293T cells were transfected with 10 g of the indicated plasmid/10-cm plate. 48 h after transfection the cells were harvested as described above for co-immunoprecipitation except adding 10 mM NaF and 1 mM NaVO 3 to Bri97 lysis buffer, precleaned for 1 h at 4°C with 50/50% (v/v) protein A/protein G mix and immunoprecipitated for 16 -18 h at 4°C with anti-HA (3F10, Roche) or anti-GFP (CLONTECH) monoclonal antibodies. After immunoprecipitation samples were washed three times with ice cold lysis buffer and twice with kinase buffer (Akt kinase assay kit, Cell Signaling Technologies). Baculoviral HA-Akt1K179D was generated as described (15) . IVK reaction was performed using GSK-3-paramyosin fusion protein (Cell Signaling Technologies) or mBAD as substrates by incubating 0.5 g of the indicated substrate proteins in the presence of 5 ng of indicated immobilized Akt and the indicated amount of GST fusion proteins (GST-TCL1, -MTCP1, -TCL1b or control) for 0 -12 min at 30°C. The total amount of GST fusion proteins in each reaction was normalized to 15 g by adding GSTcontrol protein to the reaction samples. The reaction was terminated by adding SDS sample buffer, the samples were resolved on 4 -20% Trisglycine gels (Invitrogen) and immunoblotted with anti-HA (3F10, Roche), phosphospecific anti-Akt (Ser-473), phosphospecific anti-Bad (Ser-136), and phosphospecific anti-GSK-3 (S21/9) (Cell Signaling Technologies). All kinase assays have been quantitated using the NIH Image (version 1.62) software, and the numbers (-fold increase compared with the control) are shown in each figure.
In Vivo Transphosphorylation-293 cells (ATCC) were transfected with 1 g of pEGFP-HA-Akt3 K177M (pEGFP vector, CLONTECH) together with 6 g/10-cm dish of pCMV2-Flag TCL1, pCMV2 Flag-36 -38A TCL1 (dimerization-defective mutant form of TCL1), 2 or vector control (pCMV2 Flag vector, Eastman Kodak Co.). 24 h after transfection, cells were serum-starved for 16 h before harvesting. The cells were lysed, precleaned with protein A/protein G mix, and immunoprecipitated with anti-Flag beads (M2, Kodak) or control antibody (data not shown) as described (14) . The samples were resolved on SDS-PAGE and immunoblotted with anti-phospho-Ser-473 Akt, anti-Akt, or anti-Flag antibodies as indicated.
RESULTS

Isoform Specificity of the Interaction between Members of the TCL1 Oncogene Family and Akt1, Akt2
, and Akt3-There are currently three known members of the TCL1 family (TCL1, MTCP1, and TCL1b) and three known Akt kinase isoforms (Akt1, Akt2, and Akt3). TCL1, MTCP1, and TCL1b have all been shown previously to interact with Akt1 (15) . However, because they have only 30 -50% amino acid homology, we hypothesized that they might show isoform specificity in their interaction with the other Akt kinases.
In mammalian overexpression systems using 293T cells, we first confirmed that TCL1 is capable of binding to all Akt isoforms (Fig. 1A) . The interaction is not dependent on Akt kinase activity or phosphorylation status because, in addition to wild-type Akt3, TCL1 co-immunoprecipitated with ATP-binding site mutated Akt3, and activation site mutated Akt3 (Fig. 1B) .
We next found that, in mammalian overexpression systems, Akt3 selectively interacts with TCL1, but not with MTCP1 or TCL1b (Fig. 1C) . The results were consistent in GST-pull down assays, which verified the TCL1 specificity of Akt3 binding compared with MTCP1 and TCL1b (Fig. 1D) . Similarly to Akt1 and in contrast to Akt3, Akt2 was capable of binding with TCL1 and with MTCP1 and TCL1b (data not shown).
The results indicate that, although Akt1 and Akt2 interact with all three TCL1 family members, Akt3 shows specificity for TCL1 and does not bind to MTCP1 or TCL1b.
TCL1, but Not MTCP1 or TCL1b, Enhances Akt3-dependent GSK-3␣ and BAD Phosphorylation and Facilitates Akt3 Ser-472 Phosphorylation in Vitro-Because Akt3 binds selectively to TCL1 but not to MTCP1 or TCL1b, we hypothesized that similar specificity applies to Akt3 kinase activity induction by the proteins. In in vitro Akt3 kinase assays using human Akt3 immobilized from transfected 293T cells and GSK-3␣ as substrate, we found that only the presence of TCL1 but not MTCP1 or TCL1b significantly enhanced GSK-3␣ phosphorylation. However, in the same experiment, all three TCL1 isoforms were able to enhance Akt1-dependent GSK-3␣ phosphorylation. Analogously, all three isoforms enhanced Akt2-dependent GSK-3␣ phosphorylation in vitro (Fig. 2A) .
We further confirmed the effects of TCL1 on Akt3 kinase activity in a time-course study and found that GSK-3␣ phosphorylation was enhanced in a time-dependent manner (Fig. 2B) .
To determine that the effect of TCL1 on Akt3 kinase activity was not GSK-3␣ substrate-specific, we performed in vitro kinase assays using BAD as substrate and found that TCL1 enhanced Akt3-induced BAD phosphorylation on Ser-136 in a dose-dependent fashion (Fig. 2C) . Additionally, in accordance with our previous findings that TCL1 facilitates Akt1 phosphorylation and activation, we found that the increase in BAD phosphorylation was accompanied by corresponding TCL1 dosedependent increases in Akt3 Ser-472 phosphorylation (Fig. 2C) . TCL1-induced kinase activation was Akt-specific because TCL1 did not enhance the phosphorylation on kemptide by either protein kinase A or protein kinase A-related kinase (data not shown).
The results show that, similar to the specificity of the interaction with the members of the TCL1 oncogene family, Akt1 and Akt2 kinase activity is enhanced by all family members, whereas that of Akt3 can only be induced by TCL1, but not MTCP1 or TCL1b. The PH Domain of Akt3 Is the Functional Determinant of Specificity for TCL1-In a mammalian overexpression system, we then determined that the interaction between Akt3 and TCL1 is mediated through Akt3 PH domain, because TCL1 co-immunoprecipitated with both full-length Akt3 and the PH domain of Akt3 (lanes 1-3) , but not with C-terminal Akt3 (Fig. 3A) .
As it appeared that the PH domain was the functional determinant for the TCL1 specificity of Akt3, we generated a chimeric form of Akt in which Akt3 PH domain was fused to the C terminus of Akt1 (Fig. 3B) . We then performed co-immunoprecipitation experiments and found that wild-type Akt1 interacted with all three TCL1 isoforms (Fig. 3C) , and the chimeric Akt3/Akt1 selectively bound to TCL1 but not to MTCP1 or TCL1b (Fig. 3C) . The association also showed functional selectivity because only TCL1, but not MTCP1 or TCL1b, was able In contrast, co-incubation with all three isoforms of TCL1 increased Akt1-induced GSK-3␣ phosphorylation (GST control (lane 5), TCL1 (lane 6, 3.6-fold increase compared with that with GST control), MTCP1 (lane 7, 3.6-fold increase), and TCL1b (lane 8, 3.7-fold increase), respectively). Equal amounts of immobilized HA-tagged Akt (ϳ5 ng) and GST fusion proteins (15 g) were used in the reactions (bottom row; lanes 1-4 and 5-8; control GST, GST-TCL1, GST-MTCP1, and GST-TCL1b, respectively). B, in in vitro kinase assays, co-incubation with GST-TCL1 enhanced Akt3-induced phosphorylation of GSK-3␣ compared with control GST protein in a time-dependent manner (top row; lanes 1-5 control GST versus lanes 6 -10; 0, 1, 5, 10, and 20 min, respectively). Equal amounts of immobilized HA-Akt3 were used in the reactions (bottom row). C, co-incubation with GST-TCL1 fusion protein enhanced Akt3-induced serine 136 phosphorylation of mBAD in a dose-dependent manner (top row; 1-, 2.1-, 3.1-, and 5.2-fold increase in the presence of 0, 5, 10, and 15 g of GST-TCL1, respectively). The levels of Akt3 Ser-472 phosphorylation (second row; 1-, 1.2-, 1.6-, and 4.4-fold increase in the presence of 0, 5, 10, and 15 g of GST-TCL1, respectively) were similarly enhanced in a dose-dependent manner. Equal amounts of immobilized HA-Akt3 and BAD were used (third and fourth rows).
Differential Regulation of Akt by the Proto-oncogene TCL1
to enhance GSK-3␣ phosphorylation by the chimeric Akt3/Akt1 in in vitro kinase assays (Fig. 3D) .
Together the results indicate that, despite the high degree of sequence homology (82%) between the Akt1 and Akt3 PH domains, the differences are sufficient to lead to functional differences among the Akt kinase family.
TCL1 Interacts with Akt1, Akt2, and Akt3 in TCL1-overexpressing Leukemia/Lymphoma Cell Lines and Facilitates the
Oligomerization of Akt1 with Akt3-In contrast to the Akt kinases, which are ubiquitously expressed in most tissues under normal physiological conditions, the expression of TCL1 is restricted. However, in human disease in addition to T-cell prolymphocytic leukemia (T-PLL), TCL1 is widely expressed in hematological malignancies including lymphoblastic lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia (21-23). We therefore hypothesized that, in human disease in TCL1-overexpressing cells, TCL1 could interact with all three Akt isoforms in vivo.
We first examined expression of TCL1. Both SUPT-11 (T cell leukemia) and P3HR-1 (Burkitt's lymphoma), but not SUP-T1 acute T-cell leukemia cell line, express TCL1 (Fig. 4A) . However, all three Akt isoforms are present as determined by immunoprecipitation with Akt1-, Akt2-, and Akt3-specific antibodies followed by immunoblotting with a pan-Akt antibody (data not shown). Moreover, endogenous TCL1 co-immunoprecipitated with Akt1, Akt2, and Akt3 in both SUPT-11 and P3HR-1 cells, whereas no background was observed in SUP-T1 cells (Fig. 4B) .
TCL-1 forms homo-oligomers in vivo and can associate with all Akt isoforms; we then postulated that the presence of TCL1 could facilitate the formation of oligomers encompassing differ- Flag immunoblot) . H, anti-HA; F, anti-Flag; C, anti-control antibody). B, the structure of the chimeric Akt3/Akt1 construct used in this study. To characterize the role of Akt PH domain as a functional determinant of Akt-TCL1 interaction, we generated a chimeric HA-Akt3/Akt1 construct, in which human Akt3 PH domain (amino acids 1-119) was fused with the C terminus of Akt1 (amino acids 121-480) and expressed using the mammalian expression vector PME18S-HA described previously. C, comparing the chimeric Akt3/Akt1 and wild-type Akt1, we examined the physical interaction of Akt with TCL1 family proteins. Overexpressed wild-type HA-Akt1 co-immunoprecipitated with Flag-MTCP1 (lanes 4 -6), Flag-TCL1b (lanes 10 -12) , and Flag-TCL1 (lanes 16 -18) . In contrast, the chimeric HA-Akt3/Akt1 co-immunoprecipitated solely with Flag-TCL1 (lanes 13-15), but not with Flag-MTCP1 (lanes 1-3) ent Akt isoforms. In a mammalian overexpression system, we found that co-transfection of HA-Akt1 and Flag-Akt3 with TCL1-Myc enabled the co-immunoprecipitation of Akt1 with Akt3 compared with similar transfection of Akt1 and Akt3 with an empty vector control (Fig. 4C) .
TCL1 Enhances Hetero-oligomerization of Two Akt Molecules and Facilitates
Transphosphorylation of Akt-Because TCL1 was able to induce hetero-oligomerization of Akt3 with Akt1 and autophosphorylation has been reported to be one mechanism of Akt Ser-472/473 phosphorylation, we performed in vitro kinase assays to determine whether transphosphorylation between Akt molecules could occur in the oligomeric protein complex. We generated GFP-tagged wild-type and kinase inactive Akt3. Because of the additional GFP (30-kDa mass; Fig.  5A, left panel) , GFP-Akt3 can be distinguished from non-tagged Akt (retarded migration on SDS gels). In vitro kinase assays were performed using baculovirally generated kinase-inactive K179D Akt1 (15) as a potential transphosphorylation target for GFP-wild-type Akt3. In the presence of TCL1, but not in its absence, GFP-WT Akt3 was able to enhance Ser-473 phosphorylation and of K179D Akt1 (Fig. 5A) . The effect required the presence of Akt kinase activity, as similarly prepared GFPAkt3 K177M had no effect on K179D Akt1 phosphorylation (Fig. 5A) . Together, the results demonstrate that transphosphorylation can occur between two different Akt molecules in the presence of TCL1 in vitro.
We then determined whether Akt transphosphorylation or a similar event could occur in vivo in the presence of TCL1. Kinase-inactive GFP-Akt3 K177M was co-transfected into 293 cells together with Flag-wild-type TCL1, Flag-36 -38A-TCL1 (TCL1 mutant incapable of homodimerization) 2 or sham. As shown in Fig. 5B , equal amounts of endogenous Akt and transfected GFP-Akt3 K177M co-immunoprecipitated with wildtype and dimerization-deficient 36 -38A TCL1. However, the Ser-473 phosphorylation levels of both endogenous and transfected Akt were significantly higher in cells transfected with wild-type TCL1 compared with the cells transfected with 36 -38A TCL1. Thus, TCL1 homodimerization and resulting Akt oligomerization are required for TCL1 enhanced Akt phosphorylation in vivo.
DISCUSSION
Despite the highly conserved structure and the common activation process of three mammalian Akt isoforms, there are differences in the expression pattern, regulation following cell stimulation by growth factors, and implication in the pathogenesis of specific malignancies between the isoforms. Akt1 and Akt2 are ubiquitously expressed, whereas Akt3 seems to be mainly expressed in brain, testes, kidney, heart, lung, and skeletal muscle (2, 3) . After epidermal growth factor stimulation in human esophageal cancer cell lines, differential phosphorylation of each of the isoforms has been reported (17) . Overexpression of Akt1 has been demonstrated in ϳ20% of gastric adenocarcinomas, whereas that of Akt2 in 3% of breast cancers, 12% of pancreatic cancers, and 15% of ovarian carcinomas (3). Up-regulation of Akt3 has been reported in estrogen receptor-deficient breast cancers and androgen-independent prostate cancers (24). However, any factors responsible for isoform-specific regulation of the Akt kinases have not previously been identified.
The TCL1 protein family consists of three members (TCL1, MTCP1, and TCL1b), which do not contain any known functional motifs. Proteins of the TCL1 family share a relatively low degree of amino acid homology (30 -50%), but a unique symmetrical ␤-barrel structure based on x-ray crystallographic analysis of TCL1 (25, 26) . TCL1 and TCL1b mRNA are expressed in several fetal tissues including thymus, kidney, lung (TCL1), and spleen (TCL1b). After birth expression of all family members is mainly restricted to lymphoid tissues, although TCL1b mRNA is also found in the placenta (18 -20) . The roles of the TCL1 family oncogenes in normal human physiology are not known, but they have been implicated in the development of human T-PLL secondary to chromosomal translocations, which lead to the activation of the genes by positioning to the T cell receptor ␤ or ␥ loci (18 -21) . In addition to T-PLL, TCL1 protein expression has been demonstrated in the majority of Burkitt's lymphomas, as well as in diffuse large B cell lymphoma, mantle cell lymphoma, primary cutaneous B cell lymphoma, and chronic lymphocytic leukemia (22, 23) .
Our data demonstrate that, in contrast to Akt1 and Akt2, which interact with, and the kinase activity of which is enhanced by, all three members of the TCL1 family, Akt3 only interacts with TCL1. This is the first mechanism by which Akt isoforms have been shown to be differentially regulated. We show that TCL1 enhances Akt3-induced GSK-3␣ and BAD phosphorylation in time-and dose-dependent fashion in vitro. Concurrently with the increase in kinase activity, TCL1 induced an increase in Akt3 Ser-472 phosphorylation.
The PH domain of Akt determines the specificity for interaction of the isoforms with members of the TCL1 family, as demonstrated by binding of TCL1 to the Akt3 PH domain and the functional results obtained using the chimeric Akt3/Akt1. This is in accordance with our previous findings showing that Akt2 PH domain binds to all three TCL1 family members in the yeast two-hybrid system (15) . It also further demonstrates the importance of the PH domain for mediating Akt activating protein-protein and protein-lipid interactions as shown to occur with products of the phosphoinositide 3-kinase pathway (7) .
How does the presence of TCL1 lead to enhanced Akt phosphorylation and kinase activation? It is well documented that dimerization can lead to activation of surface receptor kinases (e.g. vascular endothelial growth factor receptor, platelet-derived growth factor receptor) and their intracellular responses (27) (28) (29) . Analogous to transmembrane receptor kinases, recently intracellular non-transmembrane kinase ASK1 was shown to be activated by dimerization (30) . It has also been reported that the TEL-JAK2 fusion protein causes human leu- kemia because of oligomerization and constitutive kinase activation (31) . Further, Akt PH domain has been reported to mediate dimerization and a conditionally activated Akt fused to the hormone binding domain of estrogen receptor was able to stimulate PHAS-1 phosphorylation, suggesting that Akt dimerization may promote kinase activity (3, 32, 33) .
As demonstrated by co-immunoprecipitation assays, our data show that TCL1 binds to Akt PH domain and facilitates the formation of Akt/TCL1 hetero-oligomers in vivo. In in vitro kinase assays utilizing GFP-tagged wild-type and kinase inactive Akt, we further found that Akt molecules themselves can transphosphorylate each other on Ser-473 in the presence of TCL1. Thus, oligomerization with TCL1 brings Akt molecules to a close physical proximity, which as a consequence facilitates Akt transphosphorylation on the regulatory Ser-473 site, promoting kinase activity.
The Akt Thr-308 phosphorylation observed in the presence of TCL1 can not be readily accounted for by this model (Ref. 15 and present report). Phosphorylation of Thr-308, which is dependent on PDK1, is thought to be prerequisite for Akt activation (29) . Antisense PDK1 oligonucleotide has been shown to inhibit phosphorylation of both Thr-308 and Ser-473 of Akt (37) . However, recent studies using PDK1Ϫ/Ϫ cells suggest that phosphorylation of Ser-473 may be independent from Thr-308 phosphorylation (38) . This observation is consistent with the finding that staurosporine-insensitive Akt Ser-473 phosphorylation is independent of Thr-308 phosphorylation (35) . We demonstrate that the Akt PH domain binds to TCL1 and determines the specificity of interactions with members of the TCL1 family. The PH domain is present in over 90 proteins, including PDK1 (39) . Although TCL1 did not directly interact with PDK1 in co-immunoprecipitation assays, recent studies have suggested that Akt itself may interact with PDK1 in vivo (40) . In our experimental system of in vitro kinase assays, we cannot totally exclude the potential contamination by PDK1 or equivalent functional kinases during the immobilization process of Akt from the transfected cells. Moreover, it remains possible that TCL1 might recruit additional PH domain-bearing molecules, which could promote phosphorylation of Thr-308, into the Akt-TCL1 oligomeric complex. Additionally, whereas our data demonstrate oligomerization-induced activation of Akt in the presence of TCL1, this may also occur in the presence of other adapter molecules. Furthermore, it is possible that additional unidentified kinases capable of Akt Ser-473 phosphorylation exist. However, at least under certain circumstances, Ser-473 phosphorylation can occur through oligomerization-induced Akt-Akt transphosphorylation. Therefore, it is likely that various mechanisms may be involved in the regulation of Ser 473 site of Akt (34 -36) .
Despite the highly conserved structure and common activation process of the three mammalian Akt isoforms, there are differences in their expression pattern, in the regulation following activation by growth factors, and in association with the development of specific malignancies (3, 17, 24) . Different physiological function for the Akt family kinases have been demonstrated by knockout mice analysis (4, 5) . This implies that the isoforms may also have different roles in the pathogenesis of cancer. However, factors responsible for isoformspecific regulation of the Akt kinases have not previously been identified. Our finding that, although Akt1 and Akt2 bind to all TCL1 family members and can be activated by them, Akt3 shows specificity for TCL1, provides one such mechanism. Further, as Akt1 can hetero-oligomerize with Akt3 resulting in transphosphorylation and activation, it seems possible for Akt isoforms to influence each other to be underlain the manifestation of TCL1-overexpressing human diseases.
